Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent

British Journal of Pharmacology

Volumn 172, Issue 1, 2015, Pages 142-158

  Borrelli, Francesca ^a   Romano, Barbara ^a   Petrosino, Stefania ^b   Pagano, Ester ^a   Capasso, Raffaele ^a   Coppola, Diana ^c   Battista, Giovanni ^c   Orlando, Pierangelo ^d,e   Di Marzo, Vincenzo ^b   Izzo, Angelo A ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CNR   (Italy)

^c Ospedale dei Pellegrini   (Italy)

^d INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^e ISTITUTO NAZIONALE DI OTTICA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAZEPINE; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; MESSENGER RNA; PALMIDROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1; ANTIINFLAMMATORY AGENT; BENZENESULFONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; CAPSAICIN; DINITROBENZENESULFONIC ACID; ENDOCANNABINOID; ETHANOLAMINE DERIVATIVE; GPR55 PROTEIN, MOUSE; OLEIC ACID; OLEYLETHANOLAMIDE; PALMITIC ACID DERIVATIVE; PEROXIDASE; TRPV1 PROTEIN, MOUSE; VANILLOID RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION; INTESTINE CELL; INTESTINE MUCOSA PERMEABILITY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLON; DISEASE MODEL; DRUG EFFECTS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; INTESTINE ABSORPTION; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; BENZENESULFONATES; CAPSAICIN; COLITIS; COLON; DISEASE MODELS, ANIMAL; ENDOCANNABINOIDS; ETHANOLAMINES; INTESTINAL ABSORPTION; MALE; MICE, INBRED ICR; OLEIC ACIDS; PALMITIC ACIDS; PEROXIDASE; PPAR ALPHA; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; RNA, MESSENGER; TRPV CATION CHANNELS;

EID: 84919651844     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12907     Document Type: Article

References (78)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170: 1652-1675.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013d). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
5. Alhouayek M, Muccioli GG, (2012). The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 18: 615-625.
6. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG, (2011). Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 25: 2711-2721.
7. Ambrosino P, Soldovieri MV, Russo C, Taglialatela M, (2013). Activation and desensitization of TRPV1 channels in sensory neurons by the PPARα agonist palmitoylethanolamide. Br J Pharmacol 168: 1430-1444.
8. Andersen SN, Rognum TO, Bakka A, Clausen OP, (1998). Ki-67: a useful marker for the evaluation of dysplasia in ulcerative colitis. Mol Pathol 51: 327-332.
9. Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F, et al. (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90: 925-934.
10. Azuma YT, Nishiyama K, Matsuo Y, Kuwamura M, Morioka A, Nakajima H, et al. (2010). PPARα contributes to colonic protection in mice with DSS-induced colitis. Int Immunopharmacol 10: 1261-1267.
11. Balvers MG, Verhoeckx KC, Meijerink J, Wortelboer HM, Witkamp RF, (2013). Measurement of palmitoylethanolamide and other N-acylethanolamines during physiological and pathological conditions. CNS Neurol Disord Drug Targets 12: 23-33.
12. Bisogno T, Maurelli S, Melck D, De Petrocellis L, Di Marzo V, (1997). Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J Biol Chem 272: 3315-3323.
13. Blankman JL, Cravatt BF, (2013). Chemical probes of endocannabinoid metabolism. Pharmacol Rev 65: 849-871.
14. Borrelli F, Izzo AA, (2009). Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab 23: 33-49.
15. Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F, et al. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med (Berl) 87: 1111-1121.
16. Borrelli F, Fasolino I, Romano B, Capasso R, Maiello F, Coppola D, et al. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol 85: 1306-1316.
17. Burger D, Travis S, (2011). Conventional medical management of inflammatory bowel disease. Gastroenterology 140: 1827-1837.
18. Calignano A, La Rana G, Giuffrida A, Piomelli D, (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
19. Capasso R, Izzo AA, Fezza F, Pinto A, Capasso F, Mascolo N, et al. (2001). Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 134: 945-950.
20. Capasso R, Orlando P, Pagano E, Aveta T, Buono L, Borrelli F, et al. (2014). Palmitoylethanolamide normalizes intestinal motility in a murine model of post-inflammatory accelerated transit: involvement of CB1 receptors and TRPV1. Br J Pharmacol 171: 4026-4037.
21. Cuzzocrea S, Di Paola R, Mazzon E, Genovese T, Muià C, Centorrino T, et al. (2004). Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-alpha) in the development of inflammatory bowel disease in mice. Lab Invest 84: 1643-1654.
22. Darmani NA, Izzo AA, Degenhardt B, Valenti M, Scaglione G, Capasso R, et al. (2005). Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: review of the available pre-clinical data, and first human studies. Neuropharmacology 48: 1154-1163.
23. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V, (2006). Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570.
24. D'Argenio G, Petrosino S, Gianfrani C, Valenti M, Scaglione G, Grandone I, et al. (2007). Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med (Berl) 85: 523-530.
25. De Petrocellis L, Bisogno T, Ligresti A, Bifulco M, Melck D, Di Marzo V, (2002). Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. Fundam Clin Pharmacol 16: 297-302.
26. De Schepper HU, De Man JG, Ruyssers NE, Deiteren A, Van Nassauw L, Timmermans JP, et al. (2008). TRPV1 receptor signaling mediates afferent nerve sensitization during colitis-induced motility disorders in rats. Am J Physiol Gastrointest Liver Physiol 294: G245-G253.
27. Di Marzo V, Izzo AA, (2006). Endocannabinoid overactivity and intestinal inflammation. Gut 55: 1373-1376.
28. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, et al. (2001). Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J 358: 249-255.
29. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, et al. (2008). The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 153: 1272-1280.
30. Di Paola R, Impellizzeri D, Torre A, Mazzon E, Cappellani A, Faggio C, et al. (2012). Effects of palmitoylethanolamide on intestinal injury and inflammation caused by ischemia-reperfusion in mice. J Leukoc Biol 91: 911-920.
31. Diep TA, Madsen AN, Holst B, Kristiansen MM, Wellner N, Hansen SH, et al. (2011). Dietary fat decreases intestinal levels of the anorectic lipids through a fat sensor. FASEB J 25: 765-774.
32. Domotor A, Peidl Z, Vincze A, Hunyady B, Szolcsányi J, Kereskay L, et al. (2005). Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology 13: 161-177.
33. Esposito E, Cuzzocrea S, (2013). Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries. CNS Neurol Disord Drug Targets 12: 55-61.
34. Esposito G, Capoccia E, Turco F, Palumbo I, Lu J, Steardo A, et al. (2014). Palmitoylethanolamide improves colon inflammation through an enteric glia/toll like receptor 4-dependent PPAR-α activation. Gut 63: 1300-1312.
35. Farquhar-Smith WP, Jaggar SI, Rice AS, (2002). Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. Pain 97: 11-21.
36. Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, Mackie K, et al. (2007). Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 282: 1518-1528.
37. 2 receptor in mouse spermatogenesis. Proc Natl Acad Sci U S A 106: 11131-11136.
38. Ho WS, Barrett DA, Randall MD, (2008). 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br J Pharmacol 155: 837-846.
39. Holzer P, (2011). Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol Ther 131: 142-170.
40. Ioannidis O, Varnalidis I, Paraskevas G, Botsios D, (2011). Nutritional modulation of the inflammatory bowel response. Digestion 84: 89-101.
41. Izzo AA, Camilleri M, (2009). Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 60: 117-125.
42. Izzo AA, Piscitelli F, Capasso R, Marini P, Cristino L, Petrosino S, et al. (2010). Basal and fasting/refeeding-regulated tissue levels of endogenous PPAR-alpha ligands in Zucker rats. Obesity (Silver Spring) 18: 55-62.
43. Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, et al. (2012). Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol 166: 1444-1460.
44. Kaneko Y, Szallasi A, (2014). Transient receptor potential (TRP) channels: a clinical perspective. Br J Pharmacol 171: 2474-2507.
45. Keppel Hesselink JM, de Boer T, Witkamp RF, (2013). Palmitoylethanolamide: a natural body-own anti-inflammatory agent, effective and safe against influenza and common cold. Int J Inflam 2013: 151028.
46. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
47. Kimball ES, Wallace NH, Schneider CR, D'Andrea MR, Hornby PJ, (2004). Vanilloid receptor 1 antagonists attenuate disease severity in dextran sulphate sodium-induced colitis in mice. Neurogastroenterol Motil 16: 811-818.
48. Koning M, Ailabouni R, Gearry RB, Frampton CM, Barclay ML, (2013). Use and predictors of oral complementary and alternative medicine by patients with inflammatory bowel disease: a population-based, case-control study. Inflamm Bowel Dis 19: 767-778.
49. Kotsikorou E, Sharir H, Shore DM, Hurst DP, Lynch DL, Madrigal KE, et al. (2013). Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry 52: 9456-9469.
50. Krawisz JE, Sharon P, Stenson WF, (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87: 1344-1350.
51. Lambert DM, Di Marzo V, (1999). The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6: 757-773.
52. Li K, Feng JY, Li YY, Yuece B, Lin XH, Yu LY, et al. (2013). Anti-inflammatory role of cannabidiol and O-1602 in cerulein-induced acute pancreatitis in mice. Pancreas 42: 123-129.
53. Li Y, Yang L, Chen L, Zhu C, Huang R, Zheng X, et al. (2012). Design and synthesis of potent N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor as anti-inflammatory compounds. PLoS ONE 7: e43023.
54. Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, et al. (2011). A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogastroenterol Motil 23: 862-e342.
55. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, et al. (2005). The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol 67: 15-19.
56. Löwenberg M, D'Haens G, (2013). Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep 15: 311.
57. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, et al. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113: 1202-1209.
58. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
59. Naderi N, Majidi M, Mousavi Z, Khoramian Tusi S, Mansouri Z, Khodagholi F, (2012). The interaction between intrathecal administration of low doses of palmitoylethanolamide and AM251 in formalin-induced pain related behavior and spinal cord IL1-β expression in rats. Neurochem Res 37: 778-785.
60. de Novellis V, Luongo L, Guida F, Cristino L, Palazzo E, Russo R, et al. (2012). Effects of intra-ventrolateral periaqueductal grey palmitoylethanolamide on thermoceptive threshold and rostral ventromedial medulla cell activity. Eur J Pharmacol 676: 41-50.
61. Opheim R, Hoivik ML, Solberg IC, Moum B, (2012). Complementary and alternative medicine in patients with inflammatory bowel disease: the results of a population-based inception cohort study (IBSEN). J Crohns Colitis 6: 345-353.
62. O'Sullivan SE, Kendall DA, (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. Immunobiology 215: 611-616.
63. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res 42 (Database Issue): D1098-1106.
64. Pertwee RG, (2007). GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 152: 984-986.
65. Petrosino S, Iuvone T, Di Marzo V, (2010). N-palmitoyl-ethanolamine: biochemistry and new therapeutic opportunities. Biochimie 92: 724-727.
66. Petrosino S, Borrelli F, Pagano E, Di Marzo V, Izzo AA, (2013). Effect of Palmitoylethanolamide in a Murine Model of Colitis. 36° Congresso Nazionale della Società Italiana di Farmacologia, Turin, Italy.
67. Pfaffl MW, Horgan GW, Dempfle L, (2002). Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
68. Romano B, Borrelli F, Fasolino I, Capasso R, Piscitelli F, Cascio M, et al. (2013). The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br J Pharmacol 169: 213-229.
69. Ryberg E, Larsson N, Sjögren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
70. Schicho R, Storr M, (2012). A potential role for GPR55 in gastrointestinal functions. Curr Opin Pharmacol 12: 653-658.
71. Schicho R, Bashashati M, Bawa M, McHugh D, Saur D, Hu HM, et al. (2011). The atypical cannabinoid O-1602 protects against experimental colitis and inhibits neutrophil recruitment. Inflamm Bowel Dis 17: 1651-1664.
72. Skaper SD, Facci L, (2012). Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide. Philos Trans R Soc Lond B Biol Sci 367: 3312-3325.
73. Smart D, Jonsson KO, Vandevoorde S, Lambert DM, Fowler CJ, (2002). Entourage' effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br J Pharmacol 136: 452-458.
74. Solorzano C, Zhu C, Battista N, Astarita G, Lodola A, Rivara S, et al. (2009). Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc Natl Acad Sci U S A 106: 20966-20971.
75. Solorzano C, Antonietti F, Duranti A, Tontini A, Rivara S, Lodola A, et al. (2010). Synthesis and structure-activity relationships of N-(2-oxo-3-oxetanyl)amides as N-acylethanolamine-hydrolyzing acid amidase inhibitors. J Med Chem 53: 5770-5781.
76. 2 receptors. J Mol Med 86: 925-936.
77. Tsuboi K, Takezaki N, Ueda N, (2007). The N-acylethanolamine-hydrolyzing acid amidase (NAAA). Chem Biodivers 4: 1914-1925.
78. Ueda N, Tsuboi K, Uyama T, (2013). Metabolism of endocannabinoids and related N-acylethanolamines: canonical and alternative pathways. FEBS J 280: 1874-1894.